These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26091387)

  • 1. In Vitro Nail Penetration and Antifungal Activity of Tavaborole, a Boron-Based Pharmaceutical.
    Coronado D; Merchant T; Chanda S; Zane LT
    J Drugs Dermatol; 2015 Jun; 14(6):609-14. PubMed ID: 26091387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Nail Penetration of Tavaborole Topical Solution, 5%, Through Nail Polish on Ex Vivo Human Fingernails.
    Vlahovic T; MPharm TM; Chanda S; Zane LT; Coronado D
    J Drugs Dermatol; 2015 Jul; 14(7):675-8. PubMed ID: 26151782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tavaborole for the treatment of onychomycosis.
    Elewski BE; Tosti A
    Expert Opin Pharmacother; 2014 Jul; 15(10):1439-48. PubMed ID: 24856836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis.
    Gupta G; Foley KA; Gupta AK
    Skin Therapy Lett; 2015 Nov; 20(6):6-9. PubMed ID: 27224843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.
    Zane LT; Plattner J; Chanda S; Coronado D; Merchant T; Alley MR; Gupta AK
    Drugs Today (Barc); 2015 Oct; 51(10):599-607. PubMed ID: 26583302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis.
    Markinson B; Ghannoum M; Winter T; Rycerz A; Rock F; Gupta AK
    J Am Podiatr Med Assoc; 2018 Jan; 108(1):12-19. PubMed ID: 29547036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails.
    Gupta AK; Vlahovic TC; Foley KA; Lowe NG; Turner R; Brown M; Hall S
    J Dermatolog Treat; 2018 Sep; 29(6):633-636. PubMed ID: 29307243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole.
    Vlahovic TC; Coronado D; Chanda S; Merchant T; Zane LT
    J Drugs Dermatol; 2016 Jan; 15(1):89-94. PubMed ID: 26741386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tavaborole - a treatment for onychomycosis of the toenails.
    Gupta AK; Versteeg SG
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1145-52. PubMed ID: 27347905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.
    Gupta AK; Daigle D
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):735-42. PubMed ID: 24894552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of tavaborole for the treatment of onychomycosis.
    Gupta AK; Daigle D
    Future Microbiol; 2014; 9(11):1243-50. PubMed ID: 25437186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on tavaborole for the treatment of onychomycosis.
    Jinna S; Finch J
    Drug Des Devel Ther; 2015; 9():6185-90. PubMed ID: 26640371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.
    Elewski BE; Aly R; Baldwin SL; González Soto RF; Rich P; Weisfeld M; Wiltz H; Zane LT; Pollak R
    J Am Acad Dermatol; 2015 Jul; 73(1):62-9. PubMed ID: 25956661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
    Toledo-Bahena ME; Bucko A; Ocampo-Candiani J; Herz-Ruelas ME; Jones TM; Jarratt MT; Pollak RA; Zane LT
    J Drugs Dermatol; 2014 Sep; 13(9):1124-32. PubMed ID: 25226015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
    Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis.
    Adigun CG; Vlahovic TC; McClellan MB; Thakker KD; Klein RR; Elstrom TA; Ward DB
    J Drugs Dermatol; 2016 Sep; 15(9):1116-20. PubMed ID: 27602975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
    Hafeez F; Hui X; Selner M; Rosenthal B; Maibach H
    Drug Dev Ind Pharm; 2014 Jun; 40(6):838-44. PubMed ID: 23600655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
    Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
    J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
    Aly R; Gupta AK; Winter T; Zane LT; Vlahovic T
    J Drugs Dermatol; 2017 Oct; 16(10):1016-1021. PubMed ID: 29036255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tavaborole 5% solution for onychomycosis.
    Gupta AK; Daigle D; Abramovits W
    Skinmed; 2015; 13(1):55-8. PubMed ID: 25842473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.